In line / mixed
Organic growth was about 19.5%, with broad cardiovascular momentum and continued FARAPULSE adoption.
[AS-EXP-026]Boston Scientific
Q4 / FY2024: A clean beat and above-consensus 2025 growth plan validated the operating story but produced only modest upside at a high multiple.
ResultIn line / mixedGuidanceMixed / newly framedEnvironmentimproving
Investment snapshot
What happened and why it mattered
Mixed / newly framed
Initial 2025 organic growth was above Street expectations and supported further target-price increases.
[AS-EXP-026]No clear inflection
Initial 2025 organic growth was above Street expectations and supported further target-price increases.
[AS-EXP-026]Qualitative
The stock rose only slightly because premium valuation already discounted exceptional execution.
[AS-ME-082]Results versus expectations
The print and the three most important read-throughs
Organic growth was about 19.5%, with broad cardiovascular momentum and continued FARAPULSE adoption.
- 1
Organic growth was about 19.5%, with broad cardiovascular momentum and continued FARAPULSE adoption.
Guidance bridge
GuidanceMixed / newly framedLatest outlook and KPI implications
Initial 2025 organic growth was above Street expectations and supported further target-price increases.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| Reported net sales growth | +17.6% (FY24 actual) | +12.5% to +14.5% | ~+13.2% reported (Street) | Deceleration off peak | Updated | Tough comps, ~350bps M&A, ~100bps FX headwind |
| Organic net sales growth | +16.4% (FY24 actual) | +10% to +12% | ~+9.4% organic (Street) | Guide midpoint ~150bps above Street | Updated | Above-market growth on EP/WATCHMAN breadth |
| Adjusted EPS | $2.51 (FY24 actual) | $2.80–$2.87 (+12–14%) | ~$2.81 (Street); RAe $2.84 | Midpoint ~$2.835, +13% | Updated | Leveraged EPS growth incl. $0.05–0.06 FX headwind |
| GAAP EPS | $1.25 (FY24 actual) | $1.86–$1.93 | NOT AVAILABLE | +49–54% | Updated | Lower non-GAAP adjustments y/y |
| Adjusted operating margin expansion | 27.0% (FY24, +70bps) | +50–75 bps | NOT AVAILABLE | Continued expansion | Updated | Balance drop-through with targeted growth investment |
| Adjusted gross margin | 70.3% (FY24) | Improve vs FY2024 | ~70.8% (Street) | Modest improvement | Raised | Easing FX, favorable PFA/WATCHMAN mix |
Management signal — paraphrased
Initial 2025 organic growth was above Street expectations and supported further target-price increases.
Implied cadence
Initial 2025 organic growth was above Street expectations and supported further target-price increases.
Stock reaction
Why the shares moved
The stock rose only slightly because premium valuation already discounted exceptional execution.
- The stock rose only slightly because premium valuation already discounted exceptional execution.
Did the reaction persist?
[AS-ME-082]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentimprovingWhat management said about the operating backdrop
A clean beat and above-consensus 2025 growth plan validated the operating story but produced only modest upside at a high multiple.
- Customer demandNot stated
Not separately stated
OutlookNot separately statedKPI implicationNot separately statedSynthesis · Medium confidence · AS-ME-082 - Procedure volumes "relatively consistent," July/Aug slowdown, Sept strengtheningAF market to convert >60% to PFA by 2026
Improving
OutlookUnderpins 10-12% organic guide above ~9.4% StreetKPI implicationManagement interpretationHigh · Volumes / procedures confidence · [108] - Regional / end-market (China)Worsening
China grew strong double-digit / >$1B in '24; guided to mid-teens on "more extensive" VBP in '25
OutlookFARAPULSE + portfolio diversification to offset VBPKPI implicationChina deceleration modest drag on emerging-markets growthDisclosed fact · High confidence · [112]
- Channel / inventoryImproving
Days inventory on hand down ~11.5% y/y with DSOs down >5%, aiding FCF conversion
OutlookBalance of avoiding backorders vs improving DIOHKPI implicationFCF conversion 71%, up from ~60% in 2023Broker evidence · High confidence · AS-ME-082 - Supply availabilityStable
"We don't anticipate...supply challenges, given the investment...throughout the year"
OutlookScaling for China/Japan launches and CHAMPION-positive WATCHMANKPI implicationRemoves a key gating risk on PFA revenue upsideManagement interpretation · High confidence · [110] - Input costs / labor / utilization / capacityMixed
4Q GM 70.6% pressured by capital placements, manufacturing investment, inventory charge, FX
OutlookGM guided to improve in '25 as FX eases and PFA mix accretesKPI implication50-75bps operating-margin expansion goalBroker evidence · Medium confidence · [111]
- Competition (PFA)Worsening
"There could be stronger PFA competition in 2025. A lot of that is out of our hands"
OutlookAffera/Sphere9 ramp gated by mapping installs; Varipulse pausedKPI implicationEP durability is the swing factor for double-digit organicManagement interpretation · High confidence · [106] - PricingStable
Above-market growth "supported by price discipline"; pricing -1% to flat guided for '25
OutlookFastest-growing products (Farapulse, WATCHMAN, Agent) all GM-accretiveKPI implicationSupports gross-margin recovery toward pre-COVID highsBroker evidence · Medium confidence · [107]
Evidence and confidence
Source map
No material gap recorded.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗